Bermuda Grass Allergy: The Sour Grass That Standard Immunotherapy Misses

Grastek is a timothy grass tablet designed to treat Pooideae grass allergies through cross-reactivity. Bermuda grass (Cynodon dactylon), the dominant grass in Phoenix, Tucson, and other desert Southwest cities, belongs to subfamily Chloridoideae and completely lacks the Group 5 allergens that are the basis for Pooideae cross-reactivity. Grastek's timothy extract builds immune tolerance to Phl p 1 and Phl p 5 — proteins that bermuda does not contain. When you take Grastek and remain symptomatic during Arizona's March-through-November bermuda season, the product is performing exactly as designed; it simply was not designed for your actual allergen. A Cyn d 1 specific IgE test can confirm bermuda sensitization and redirect your treatment toward an immunotherapy containing bermuda extract.

Cyn d 1 is the Group 1 major allergen of Cynodon dactylon (bermuda grass) — a beta-expansin protein that is the most important IgE target in bermuda sensitization, recognized by the majority of bermuda-allergic patients. Like all Group 1 grass allergens, Cyn d 1 shares structural homology with Phl p 1 (timothy) and other Group 1 proteins, but it carries unique epitopes that are NOT recognized by anti-Phl p 1 IgE. This is why bermuda-allergic patients do not benefit from timothy-based immunotherapy even though both grasses have Group 1 proteins. Cyn d 1 specific IgE testing is the most clinically actionable diagnostic test for identifying bermuda sensitization and distinguishing it from Pooideae sensitization (identified by Phl p 5). The combination of Cyn d 1 and Phl p 5 test results determines which extracts are needed for effective immunotherapy.

Yes, dual sensitization to both bermuda (Chloridoideae) and Pooideae grasses is common in transition-zone states and areas where bermuda and cool-season grasses coexist, such as Kentucky, Tennessee, Virginia, and the Carolinas. A patient with dual sensitization has two separate IgE populations — Cyn d 1-specific IgE for bermuda and Phl p 5-specific IgE for Pooideae. The clinical implication is that two separate immunotherapy extracts are required: bermuda extract (Cyn d 1) in one component and a Pooideae representative (timothy) in a separate formulation, as they cannot be mixed in the same SCIT vial. Component testing showing both Cyn d 1 and Phl p 5 positive confirms dual sensitization and guides the two-extract treatment plan.

Phoenix is a desert environment where bermuda grass would not exist naturally — it is entirely maintained by irrigation of residential lawns, golf courses, athletic fields, and roadside medians. This creates an artificial pollen source in a region with otherwise minimal background grass pollen. The Phoenix metropolitan area encompasses millions of irrigated bermuda lawn acres that collectively produce enormous spring and summer pollen loads. Bermuda pollinates from approximately March through November in Phoenix, producing one of the longest grass pollen seasons of any US city. The Phoenix City Council enacted an Airborne Pollen Ordinance specifically targeting bermuda grass mowing height because mowing stimulates pollen production. This combination of massive irrigation-dependent bermuda coverage and a nine-month season makes Phoenix one of the highest bermuda pollen burden cities in the United States.

The most reliable way to distinguish bermuda from Pooideae grass sensitization is component-resolved testing for Cyn d 1 (bermuda marker) and Phl p 5 (Pooideae marker). High Cyn d 1 with negative Phl p 5 indicates primary bermuda sensitization. Positive Phl p 5 indicates Pooideae sensitization. Both positive indicates dual sensitization. Clinically, several patterns suggest bermuda predominance: symptoms in the South or Southwest that persist from March through November, symptoms that have not improved on Grastek or Oralair, and symptom onset correlated with living in or visiting Sun Belt cities. Standard total IgE grass panels without component testing often miss the bermuda-versus-Pooideae distinction, so specifically requesting Cyn d 1 and Phl p 5 is essential for accurate diagnosis.

In some regions, bermuda allergy approaches year-round symptomatic duration. In the warmest areas of Southern California and South Florida, bermuda pollen can be detected in all 12 months. In most Sun Belt cities, the March through November season (nine months) creates symptoms long enough that the two-month winter reprieve may be perceived as merely a reduced-symptom period rather than a complete break. When bermuda is combined with co-occurring weed pollen seasons (ragweed August through October, sagebrush and tumbleweed August through September in the Southwest), sensitized patients in the South and Southwest can have effectively continuous allergic symptoms across most of the year. This near-perennial symptom pattern is why bermuda allergy is sometimes confused with perennial allergic rhinitis caused by dust mites or mold rather than recognized as seasonal.

Yes, bermuda grass sensitization is associated with allergic asthma, and the extended nine-month pollen season creates a particularly significant asthma risk compared to the brief Pooideae grass season. Approximately 30 to 40% of patients with grass pollen rhinitis have measurable bronchial hyperreactivity, and the sustained eosinophilic airway inflammation from a nine-month bermuda exposure window drives more persistent airway remodeling than a 6 to 8 week Pooideae season. Sun Belt epidemiological studies show bermuda pollen counts correlate with emergency department asthma visit rates. Bermuda-sensitized patients with any asthma history should have current asthma medications accessible throughout the March through November season and should discuss long-term disease-modifying immunotherapy with an allergist to reduce both nasal symptom burden and bronchial hyperreactivity.

No. Neither Grastek (timothy), Oralair (5-grass), nor Ragwitek (ragweed) covers bermuda grass. Grastek and Oralair specifically target Pooideae grasses and provide no cross-reactivity benefit for bermuda. This regulatory gap means bermuda-sensitized patients must rely on either subcutaneous immunotherapy (SCIT) using the FDA-standardized bermuda extract (g2, 10,000 BAU/mL — which must be placed in a separate vial from any Pooideae extracts), or custom-compounded sublingual immunotherapy drops containing bermuda extract. Custom SLIT drops can include bermuda as one of multiple allergen extracts in a single formulation, addressing the practical complexity of treating a patient sensitized to bermuda plus Pooideae grasses plus other allergens in one daily home regimen.

The Phoenix Airborne Pollen Ordinance is a municipal regulation specifically targeting plants that produce high airborne pollen loads in the Phoenix metropolitan area. For bermuda grass, the ordinance restricts mowing height during pollination periods, because mowing bermuda stimulates renewed seed-head formation and pollen production. The ordinance also targets male olive and mulberry trees, which produce significant spring pollen loads. Phoenix enacted this ordinance in recognition of the public health burden of bermuda and tree pollen in a city where irrigated landscapes create artificial pollen loads in a natural desert environment. Residents who identify neighboring properties with bermuda lawns being maintained in violation of the ordinance's height restrictions can report these violations to Phoenix city code enforcement, providing a legal mechanism for addressing neighborhood pollen burden.

Relocation is a significant life decision and is generally not necessary when effective diagnosis and treatment are available. Bermuda-specific immunotherapy — either SCIT with bermuda extract in a separate vial or custom SLIT drops — can meaningfully reduce the immune response to bermuda over 3 to 5 years of treatment, enabling patients to live comfortably in Sun Belt environments with standard pharmacological management rather than intensive avoidance or relocation. However, relocation to bermuda-free climates (the Pacific Northwest, upper Midwest, New England) does provide genuine allergy relief, and some patients find that the quality-of-life improvement justifies the life disruption. Before considering relocation, a discussion with an allergist about the expected trajectory of bermuda-specific immunotherapy provides the most informed basis for that decision.